A Phase 2 Study to ADX-097 in ANCA-Associated Vasculitis
Latest Information Update: 13 Aug 2024
At a glance
- Drugs ADX-097 (Primary)
- Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis
- Focus Adverse reactions
Most Recent Events
- 13 Aug 2024 New trial record
- 08 Aug 2024 According to a Q32 Biomedia release, the company expects to initiate this trial in the first half of next year, with topline results expected in the second half of 2025.